Company Overview and News

 
Q1 ETF Inflows Dive at BlackRock: Tough Road Ahead?

2018-04-13 zacks
Unlike preceding quarters,net asset inflows to BlackRock Inc.’s (BLK - Free Report) ETF business dropped 46% in the first quarter to $34.6 billion from the year-ago quarter. However, despite a decline in inflows, BlackRock’s first-quarter 2018 adjusted earnings came in at $6.70 per share, which breezed past the Zacks Consensus Estimate of $6.42.
Upvote Downvote

 
Is IEMG A Better Play For International Markets Exposure Than IXUS?

2018-04-08 seekingalpha
The iShares Core MSCI Emerging Markets ETF (IEMG) is a top-shelf choice for investors looking to gain exposure to emerging markets.
Upvote Downvote

 
IEMG: Low Cost Emerging Market Exposure

2018-04-04 seekingalpha
Emerging markets should outperform the US market going forward, and IEMG is a great way to get core, high dividend exposure.
Upvote Downvote

 
Winning ETF Areas of March

2018-04-02 zacks
The month of March was all about the Fed rate hike, trade war fears, the tech market crash and a moderation in Treasury bond yields. Let’s see how investors reacted to this situation and where they parked their money in the month. The data are as of etf.com (as of March 29, 2018) (read: ETF Asset Report for First Quarter of 2017).
Upvote Downvote

 
Wining ETF Areas of March

2018-04-02 zacks
The month of March was all about the Fed rate hike, trade war fears, the tech market crash and a moderation in Treasury bond yields. Let’s see how investors reacted to this situation and where they parked their money in the month. The data are as of etf.com (as of March 29, 2018) (read: ETF Asset Report for First Quarter of 2017).
Upvote Downvote

 
Q1 ETF Asset Report: Developed Markets Win, High-Yield Loses

2018-03-29 zacks
The markets were more tensed than relaxed in the first quarter of 2018. Increasing inflationary expectations and rising rate fears pushed up bond yields and spurred equity sell-offs in late January and early February. Then, Trump-induced trade fear (thanks to his announcement of import tariffs) and a tech rout in March did the rest of the damage (read: 5 Reason Why FANG ETFs Lost Their Charm in March).
Upvote Downvote

 
What Lies Ahead for Emerging Market ETFs?

2018-03-28 zacks
Per Goldman Sachs analysis, the recent selloff in the global market has lowered emerging market valuations and added to the appeal of such investments. Moreover, performance and fund flows have been attractive for investments in emerging markets (read: 3 ETFs to Benefit as Faster Rate Hike Worries Cool Down).
Upvote Downvote

 
Reiterate Our Overweight To Emerging Markets

2018-03-19 seekingalpha
Back in November we urged investors to evaluate their asset allocation and consider increasing their EM exposure.
Upvote Downvote

 
ETF Month #4: Developed Markets (Ex-North America) With EFA. But Is There A Better Alternative?

2018-03-18 seekingalpha
During "ETF Month", I plan to survey a number of ETFs that have a lot of followers on Seeking Alpha, but for some reason don't have much coverage on the site. Hopefully, this will improve the visibility of Cambridge Income Laboratory and draw more members to our service, allowing me to make the newsletter better than ever. I will also be taking ETF suggestions, so do let me know if you have any ETFs on your horizon.
Upvote Downvote

1
Inside February ETF Asset Report

2018-03-02 zacks
February 2018 will be remembered for the brake that the Trump Rally hit after a long and smooth journey. Several market watchers persistently warned of overvaluation and investors have showed amazing patience so far. But the U.S. market crashed to start February.
Upvote Downvote

1
Which Emerging Markets Index Is Best?

2018-02-14 seekingalpha
With the US stock market trading at a P/E of around 24, international developed markets at around a P/E of 16, emerging markets are one of the cheapest equity asset classes (with a P/E of around 15). However, not all emerging market ETFs are created equal. In this article we'll go over some of the subtle differences between the four largest emerging market ETFs. We'll look at Vanguard FTSE Emerging Markets ETF (VWO) with $68B in assets, iShares Core MSCI Emerging Markets ETF (IEMG) with $45B in assets, iShares MSCI Emerging Markets ETF (EEM) with $41B in assets, and Schwab Emerging Markets Equity ETF (SCHE) with $5B in assets.
Upvote Downvote

 
IEMG / iShares Core MSCI Emerging Markets ETF / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 1 ISHARES CORE MSCI EMERGING MARKETS ETF COMMON STOCK Cusip #46434G103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #46434G103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 28,528,758 Item 6: 0 Item 7: 31,778,205 Item 8: 0 Item 9: 31,778,205 Item 11: 4.
Upvote Downvote

 
IEMG / iShares Core MSCI Emerging Markets ETF / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 1 ISHARES CORE MSCI EMERGING MARKETS ETF COMMON STOCK Cusip #46434G103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #46434G103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 28,528,758 Item 6: 0 Item 7: 31,778,205 Item 8: 0 Item 9: 31,778,205 Item 11: 4.
Upvote Downvote

 
January ETF Asset Report: S&P 500 Wins, High-Yield Loses

2018-02-02 zacks
The month of January was all about Trump bump, cheering the tax reform, reassuring earnings, global economic growth and rising Treasury bond yields. Overall, markets remained upbeat though equities slipped at the end (read: Is it Time to Buy the Dip with ETFs?).
Upvote Downvote

 
U.S. Weekly FundFlows Insight Report: Long-Term Assets Attract Inflows For The Week

2018-02-02 seekingalpha
For the second week in three, investors were net sellers of fund assets (including those of conventional funds and ETFs), withdrawing $6.0 billion. However, the headline number once again was a little misleading. Fund investors were net redeemers of money market funds, withdrawing $26.0 billion, but they were net purchasers of long-term assets, padding the coffers of equity funds (+$16.2 billion), taxable bond funds (+$3.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 46434G103